Peptide record

TPDB84089

Pexiganan MSI-78 Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard modified_plain modified

22 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB84089

Peptide_Name

Pexiganan MSI-78

Activity

Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Immunity and inflammation peptides Toxicity and safety peptides

Database_Source

Peptipedia AntiBP3 dbAMP DRAMP ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb i2APP HemoPI Hemolytic2 PD_Hemolysis DBAASP

Sequence_Type

standard modified_plain

Has_Modification Yes

Description A 22-aa standard natural and modified multi-activity (Anti-inflammatory, Antibacterial, Anticancer, and other sources) peptide sequence curated from Peptipedia, AntiBP3, dbAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GIGKFLKKAKKFGKAFVKILKK-NH2

FASTA

>TPDB84089|Anti-inflammatory;Antibacterial;Anticancer;Antifungal;Antiparasitic;Hemolysis;Toxicity|length=22
GIGKFLKKAKKFGKAFVKILKK-NH2

Formula C122H209N31O23

Absent Amino Acids RNDCEQHMPSTWY

Common Amino Acids K

Mass 2478.20

PI 11.41

Basic Residues 9

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +9

Boman Index 3.54

Hydrophobicity -0.159

Aliphatic Index 93.18

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

Amino Acid Distribution

A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 2 L: 2 K: 9 M: 0 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

Formula

C122H209N31O23

Mass

2478.20

11.41

Net Charge

Boman Index

3.54

Hydrophobicity

-0.159

C_terminal_Modification

Amidation AMD

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial Anticancer

Origin

Helical peptide with a predominance of one or more amino acids tryptophane-rich FLAK peptides Analog of Magainin Analog of magainin 2

Evidence 1 Activity

Activity

Activity Raw

75% Cytotoxicity at 0.5 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Lymphoma Cancer

Cell Line U-937

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 1994

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =31 µg/ml

Detail Source Activity Anticancer

Activity Measurement 31 µg/mL

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 3 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =34 µg/ml

Detail Source Activity Anticancer

Activity Measurement 34 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-480

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 4 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =140 µg/ml

Detail Source Activity Anticancer

Activity Measurement 140 µg/mL

Target

Cancer Type Skin Cancer

Cell Line BMKC

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 5 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =150 µg/ml

Detail Source Activity Anticancer

Activity Measurement 150 µg/mL

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 6 Activity

Activity

Activity Endpoint LD50

Activity Raw

LD50 =66 µg/ml

Detail Source Activity Anticancer

Activity Measurement 66 µg/mL

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 7 Activity

Activity

Activity Raw

Not Available

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2005

Patents US_06875744_B2

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =20-30 µg/ml

Detail Source Activity Anticancer

Activity Measurement 20-30 µg/mL

Target

Cancer Type Lymphoma Cancer

Cell Line U-941

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 9 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50= 8 at 100 µM

Detail Source Activity Anticancer

Activity Measurement 8

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 10 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50= 6 at 100 µM

Detail Source Activity Anticancer

Activity Measurement 6

Target

Cancer Type Prostate cancer

Cell Line LNCaP

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 11 Activity

Activity

Activity Endpoint LC50

Activity Raw

LC50= 13 at 100 µM

Detail Source Activity Anticancer

Activity Measurement 13

Target

Cancer Type Ovarian Cancer

Cell Line OVRCAR-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 12 Activity

Target

Target Organism Cutibacterium acnes

Source & Reference

Database Source DBAASP